Gut Microbiome Modulation for Checkpoint Therapy Toxicity

The patent introduces the gut microbiome as an intermediary mediator between the combination immunotherapy and the host immune system. Specific bacterial species (e.g., Bacteroides, Akkermansia, Alistipes) serve as mediators that modulate the immune response to enhance anti-tumor efficacy while simultaneously reducing severe toxicities. The microbiome acts as a biological buffer that fine-tunes the intensity and specificity of T-cell activation, preventing excessive systemic immune activation that leads to toxicities.

The patent applies local quality by targeting specific gut microbiome compartments and bacterial species rather than applying systemic immunosuppression. By identifying and modulating specific bacterial populations in the gut that are associated with reduced toxicities, the treatment achieves localized immunomodulation that preserves systemic anti-tumor immunity while protecting against adverse events in specific organs.

The gut microbiome serves as an intermediary that maintains self-tolerance while allowing enhanced anti-tumor immunity. Specific bacterial species produce metabolites and molecular patterns that selectively educate and regulate T-cell responses, preserving recognition of self-antigens while enhancing responses to tumor antigens. This intermediary layer prevents direct loss of tolerance that would occur with unchecked checkpoint inhibition.

The patent utilizes parameter changes in the gut microbiome composition and metabolic profile to modulate immune response characteristics. By changing the abundance and diversity of specific bacterial species, the system alters the immunological parameters of T-cell activation, shifting the balance between anti-tumor efficacy and self-tolerance maintenance without requiring direct manipulation of checkpoint molecules.

The patent applies preliminary action by modulating the gut microbiome before and during combination immunotherapy to prevent high-grade toxicities from developing in the first place. By establishing a protective microbiome profile at the outset of treatment, patients can maintain continuous therapy without discontinuation, eliminating the time loss associated with treatment interruptions and subsequent immunosuppression management.

The patent converts the potential harm of checkpoint blockade-induced immune activation into benefit by harnessing the gut microbiome's ability to selectively regulate immune responses. The microbiome transforms the indiscriminate immune activation that causes toxicities into a targeted anti-tumor response, allowing continuous treatment while protecting against adverse events.